Researchers at NYU Langone Medical Center have discovered a new mechanism by which the deadly Staphylococcus aureus bacteria attack and kill off immune cells. Their findings, published today in the journal Cell Host & Microbe, explain a critical survival tactic of a pathogen that causes more skin and heart infections than any other microbe, and kills more than 100,000 Americans every year.
"What we've found is that Staph unleashes a multi-purpose toxin capable of killing different types of immune cells by selectively binding to surface receptors," says Victor J. Torres, PhD, assistant professor of microbiology, and senior author of the study. "Staph has evolved the clever ability to target the immune system at different stages."
Scientists have long known that Staph releases an arsenal of toxins to puncture immune cells and clear the way for infection. But only recently have they begun to understand exactly how these toxins work. Earlier this year, Dr. Torres and his team published a paper in Nature explaining how one of those toxins, a protein called LukED, fatally lyses T-cells, macrophages and dendritic cells, all types of white blood cells that help fight off infection. The LukED toxin, they showed, binds to a surface receptor called CCR5 (the same one exploited by HIV). "It attaches to the surface receptor and then triggers pore formation," says Dr. Torres. But their discovery failed to explain how the bacterial toxin kills other types of white blood cells, such as neutrophils, that lack the CCR5 receptor.
Their most recent work solves this puzzle, showing for the first time how receptors on neutrophils (a common type of white blood cell) also enable binding of the LukED toxin. The researchers found that LukED latches onto surface receptors called CXCR1 and CXCR2, creating the same deadly pores that it does when it latches onto CCR5 receptors. "The mechanism is the same," says Dr. Torres. "The strategy makes Staph deadlier in mice."
Neutrophils are the first responders. Upon infection, they race through the bloodstream to kill off the invading pathogen. "They're like the marines of the immune system," Dr. Torres says. T-cells, macrophages and dendritic cells rush in later, mounting a secondary attack to help the body clear the pathogen and remember it in the future. "Killing off the first responders completely disarms the immune system," Dr. Torres says.
LukED is just one piece of the puzzle, and more research is needed to understand other Staph toxins and how they work together to make the microbe deadlier. However, these recent insights hold promise for new medications that target LukED. Better treatments against Staph are desperately needed. In 2005, the Centers for Disease Control and Prevention estimated that more than half of the 478,000 people hospitalized for staph infections were resistant to methicillin, one of the most potent antibiotics available.
One therapeutic strategy is to block CCR5 receptors and spare the secondary immune response. "We know we can block CCR5 receptors without crippling the rest of the immune system. Some people lack CCR5 and they are perfectly healthy and immune to HIV as well," Dr. Torres says. "But just blocking CCR5 isn't enough." Drugs are available to block CXCR1 and CXCR2 receptors, but those will impair neutrophil recruitment and function. "The lesson is to target the toxin itself and prevent it from attaching to any receptors," Dr. Torres adds. "We have to think globally."
Explore further: A drug used to treat HIV might defuse deadly staph infections
Medical Xpress on facebook
Related Stories
A drug used to treat HIV might defuse deadly staph infections
Dec 14, 2012
A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hos ...
Molecular structure reveals how HIV infects cells
Sep 12, 2013
In a long-awaited finding, a team of Chinese and US scientists has determined the high-resolution atomic structure of a cell-surface receptor that most strains of HIV use to get into human immune cells. The ...
How HIV infects cells
Sep 27, 2013
In a long-awaited finding, an international team of scientists using high-brightness x-rays from the U.S. Department of Energy Office of Science's Advanced Photon Source at Argonne National Laboratory has ...
Bacterial toxins cause deadly heart disease
Aug 20, 2013
University of Iowa researchers have discovered what causes the lethal effects of staphylococcal infective endocarditis - a serious bacterial infection of heart valves that kills approximately 20,000 Americans each year.
Potent mechanism helps viruses shut down body's defense system against infection
Aug 14, 2013
Researchers at the Salk Institute for Biological Studies have discovered a powerful mechanism by which viruses such as influenza, West Nile and Dengue evade the body's immune response and infect humans with these potentially ...
Recommended for you
Runners suffer more inflammation and muscle damage than cyclists
19 hours ago
New scientific findings give endurance runners a reason to consider varying their training regime to include other sports.
Understanding inflammation
Oct 14, 2013
German scientists at Charité – Universitätsmedizin Berlin for he first time have solved the 3-dimensional structure of the protein LBP and it´s genetic variant. This finding may help certain patients to better survive ...
Immune system discovery could lead to EBV vaccine to prevent mono, some cancers
Oct 11, 2013
Development of a vaccine against Epstein-Barr virus (EBV) has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system.
Tackling allergies through collaborative research and education
Oct 10, 2013
The EU-funded Global Allergy and Asthma European Network (GA2LEN), launched in 2004, has become a leading force in the battle against allergic diseases. The network is still expanding, with over 60 centres ...
Cigarette alternatives may not be 'safe' tobacco
Oct 09, 2013
Cigarette alternatives, widely perceived to be safe, are often addictive and can be stepping stones to cigarette smoking, according to a scientific review published online in the journal Clinical Reviews in Allergy and Im ...
Study describes effects of prenatal environmental stressors on regulation of microRNAs
Oct 07, 2013
The Leipzig Helmholtz Center for Environmental Research has gained new insights on the influence of tobacco smoke in utero. For the first time, it could be demonstrated with smoking pregnant women and their ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Researchers at NYU Langone Medical Center have discovered a new mechanism by which the deadly Staphylococcus aureus bacteria attack and kill off immune cells. Their findings, published today in the journal Cell Host & Microbe, explain a critical survival tactic of a pathogen that causes more skin and heart infections than any other microbe, and kills more than 100,000 Americans every year.
"What we've found is that Staph unleashes a multi-purpose toxin capable of killing different types of immune cells by selectively binding to surface receptors," says Victor J. Torres, PhD, assistant professor of microbiology, and senior author of the study. "Staph has evolved the clever ability to target the immune system at different stages."
Scientists have long known that Staph releases an arsenal of toxins to puncture immune cells and clear the way for infection. But only recently have they begun to understand exactly how these toxins work. Earlier this year, Dr. Torres and his team published a paper in Nature explaining how one of those toxins, a protein called LukED, fatally lyses T-cells, macrophages and dendritic cells, all types of white blood cells that help fight off infection. The LukED toxin, they showed, binds to a surface receptor called CCR5 (the same one exploited by HIV). "It attaches to the surface receptor and then triggers pore formation," says Dr. Torres. But their discovery failed to explain how the bacterial toxin kills other types of white blood cells, such as neutrophils, that lack the CCR5 receptor.
Their most recent work solves this puzzle, showing for the first time how receptors on neutrophils (a common type of white blood cell) also enable binding of the LukED toxin. The researchers found that LukED latches onto surface receptors called CXCR1 and CXCR2, creating the same deadly pores that it does when it latches onto CCR5 receptors. "The mechanism is the same," says Dr. Torres. "The strategy makes Staph deadlier in mice."
Neutrophils are the first responders. Upon infection, they race through the bloodstream to kill off the invading pathogen. "They're like the marines of the immune system," Dr. Torres says. T-cells, macrophages and dendritic cells rush in later, mounting a secondary attack to help the body clear the pathogen and remember it in the future. "Killing off the first responders completely disarms the immune system," Dr. Torres says.
LukED is just one piece of the puzzle, and more research is needed to understand other Staph toxins and how they work together to make the microbe deadlier. However, these recent insights hold promise for new medications that target LukED. Better treatments against Staph are desperately needed. In 2005, the Centers for Disease Control and Prevention estimated that more than half of the 478,000 people hospitalized for staph infections were resistant to methicillin, one of the most potent antibiotics available.
One therapeutic strategy is to block CCR5 receptors and spare the secondary immune response. "We know we can block CCR5 receptors without crippling the rest of the immune system. Some people lack CCR5 and they are perfectly healthy and immune to HIV as well," Dr. Torres says. "But just blocking CCR5 isn't enough." Drugs are available to block CXCR1 and CXCR2 receptors, but those will impair neutrophil recruitment and function. "The lesson is to target the toxin itself and prevent it from attaching to any receptors," Dr. Torres adds. "We have to think globally."
Explore further: A drug used to treat HIV might defuse deadly staph infections
Medical Xpress on facebook
Related Stories
A drug used to treat HIV might defuse deadly staph infections
Dec 14, 2012
A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hos ...
Molecular structure reveals how HIV infects cells
Sep 12, 2013
In a long-awaited finding, a team of Chinese and US scientists has determined the high-resolution atomic structure of a cell-surface receptor that most strains of HIV use to get into human immune cells. The ...
How HIV infects cells
Sep 27, 2013
In a long-awaited finding, an international team of scientists using high-brightness x-rays from the U.S. Department of Energy Office of Science's Advanced Photon Source at Argonne National Laboratory has ...
Bacterial toxins cause deadly heart disease
Aug 20, 2013
University of Iowa researchers have discovered what causes the lethal effects of staphylococcal infective endocarditis - a serious bacterial infection of heart valves that kills approximately 20,000 Americans each year.
Potent mechanism helps viruses shut down body's defense system against infection
Aug 14, 2013
Researchers at the Salk Institute for Biological Studies have discovered a powerful mechanism by which viruses such as influenza, West Nile and Dengue evade the body's immune response and infect humans with these potentially ...
Recommended for you
Runners suffer more inflammation and muscle damage than cyclists
19 hours ago
New scientific findings give endurance runners a reason to consider varying their training regime to include other sports.
Understanding inflammation
Oct 14, 2013
German scientists at Charité – Universitätsmedizin Berlin for he first time have solved the 3-dimensional structure of the protein LBP and it´s genetic variant. This finding may help certain patients to better survive ...
Immune system discovery could lead to EBV vaccine to prevent mono, some cancers
Oct 11, 2013
Development of a vaccine against Epstein-Barr virus (EBV) has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system.
Tackling allergies through collaborative research and education
Oct 10, 2013
The EU-funded Global Allergy and Asthma European Network (GA2LEN), launched in 2004, has become a leading force in the battle against allergic diseases. The network is still expanding, with over 60 centres ...
Cigarette alternatives may not be 'safe' tobacco
Oct 09, 2013
Cigarette alternatives, widely perceived to be safe, are often addictive and can be stepping stones to cigarette smoking, according to a scientific review published online in the journal Clinical Reviews in Allergy and Im ...
Study describes effects of prenatal environmental stressors on regulation of microRNAs
Oct 07, 2013
The Leipzig Helmholtz Center for Environmental Research has gained new insights on the influence of tobacco smoke in utero. For the first time, it could be demonstrated with smoking pregnant women and their ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment